x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230838
| Product Information | |
|---|---|
| CAS No. | 491833-30-8 |
| Formula | C24H38N2O4 |
| Molecular Weight | 418.57 |
| SMILES | CCCCCCCCC(=O)NC(CN1CCCC1)C(O)C2=CC=C3OCCOC3=C2 |
| Target | GL1 synthase |
| Product Description | Genz-123346 is an inhibitor of GL1 synthase that blocks the conversion of ceramide to GL1, the first step in the biosynthesis of gangliosides and other glycosphingolipids. |
| Format & Storage | |
|---|---|
| Purity | > 99% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
